Background The Toronto Psoriatic Arthritis Screen II (ToPAS II) questionnaire was developed and validated in Canada. It is simple index which is very good at classifying those who are not diagnosed with Psoriatic Arthritis (PsA) and those who are diagnosed with PsA.
Objectives To assess the validity of ToPAS II questionnaire in a Turkish population.
Methods The Turkish translation of ToPAS was sent us by the developer authors of the original index. Subjects were recruited from Psoriasis (Dermatology), Psoriatic Arthritis (PsA), Physical and Rehabilitation Medicine (PRM) and Rheumatology (non PsA) clinics. All subjects were assessed by a rheumatologist according to a Standard protocol which includes demographic parameters, physical examination, ToPAS questionnaire and CASPAR criteria. Receiver Operating Characteristics (ROC) assessed to obtain sensitivty and specificity of Turkish version of ToPAS II questionnaire.
Results One hundred and fifty subjects were recruited in all groups. The mean of age was 41.07 years (SD:12,60) and the 58% of subjects were female. There were 46 subjects from psoriasis group, 43 subjects from PsA group, 41 subjects PRM group and 20 subjects from rheumatology (non-PsA) group. The area under the ROC curve was 0,985 which means as good predictor. An observed overall sensitivity and specificity, based on a single cut point of 81.2% and 99.0%.
Conclusions The Turkish version of ToPAS II has high sensitivity and specificity to screen subjects for PsA. It is very practical, not time consuming and accurate index.
Gladman DD, Schentag CT, Tom BDM et al. Development and initial validation of a screening questionnaire for psoriatic arthritis: the Toronto Psoriatic Arthritis Screen (ToPAS). Ann Rheum Dis 2009;68:497-501.
Disclosure of Interest None declared